NewLink Genetics Corp. (NASDAQ:NLNK) traded down 4.5% during mid-day trading on Tuesday . The company traded as low as $10.38 and last traded at $10.41, with a volume of 103,869 shares traded. The stock had previously closed at $10.90.

Several brokerages recently issued reports on NLNK. Zacks Investment Research cut NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Robert W. Baird reiterated a “buy” rating on shares of NewLink Genetics Corp. in a research note on Monday, May 16th. Jefferies Group reiterated a “hold” rating and issued a $10.00 price target on shares of NewLink Genetics Corp. in a research note on Wednesday, May 11th. SunTrust Banks Inc. cut NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and cut their price target for the company from $59.00 to $12.00 in a research note on Tuesday, May 10th. Finally, Mizuho cut their price target on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $23.29.

The company’s 50-day moving average is $11.18 and its 200 day moving average is $17.50. The stock’s market capitalization is $298.42 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last posted its quarterly earnings data on Friday, April 29th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.70) by $0.88. The firm earned $4.34 million during the quarter, compared to analysts’ expectations of $2.08 million. Analysts anticipate that NewLink Genetics Corp. will post ($2.83) EPS for the current year.

Other large investors have recently bought and sold shares of the company. California State Teachers Retirement System raised its stake in NewLink Genetics Corp. by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 38,523 shares of the company’s stock valued at $1,402,000 after buying an additional 636 shares during the period. EQIS Capital Management raised its stake in shares of NewLink Genetics Corp. by 587.5% in the fourth quarter. EQIS Capital Management now owns 41,644 shares of the company’s stock valued at $1,515,000 after buying an additional 35,587 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of NewLink Genetics Corp. by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 48,507 shares of the company’s stock valued at $1,765,000 after buying an additional 300 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in shares of NewLink Genetics Corp. by 134.1% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 54,775 shares of the company’s stock valued at $1,993,000 after buying an additional 31,375 shares during the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of NewLink Genetics Corp. by 5.6% in the fourth quarter. GSA Capital Partners LLP now owns 65,571 shares of the company’s stock valued at $2,386,000 after buying an additional 3,498 shares during the last quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.